Literature DB >> 11550277

Chronic myelogenous leukemia: laboratory diagnosis and monitoring.

Y L Wang1, A Bagg, W Pear, P C Nowell, J L Hess.   

Abstract

Rapid developments have occurred both in laboratory medicine and in therapeutic interventions for the management of patients with chronic myelogenous leukemia (CML). With a wide array of laboratory tests available, selecting the appropriate test for a specific diagnostic or therapeutic setting has become increasingly difficult. In this review, we first discuss, from the point of view of laboratory medicine, the advantages and disadvantages of several commonly used laboratory assays, including cytogenetics, fluorescence in situ hybridization (FISH), and qualitative and quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). We then discuss, from the point of view of clinical care, the test(s) of choice for the most common clinical scenarios, including diagnosis and monitoring of the therapeutic response and minimal residual disease in patients treated with different therapies. The purpose of this review is to help clinicians and laboratory physicians select appropriate tests for the diagnosis and monitoring of CML, with the ultimate goal of improving the cost-effective usage of clinical laboratories and improving patient care. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11550277     DOI: 10.1002/gcc.1171

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2002-02       Impact factor: 5.568

Review 2.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

3.  Persistence of derivative chromosome 22 after achieving a major molecular response in chronic myeloid leukemia with a cryptic BCR-ABL1 fusion gene.

Authors:  Hiromichi Matsushita; Atsuko Masukawa; Satoshi Arakawa; Yoshiaki Ogawa; Satomi Asai; Miharu Yabe; Kiyoshi Ando; Hayato Miyachi
Journal:  Int J Hematol       Date:  2009-12-10       Impact factor: 2.490

4.  Evaluation of a novel multiplex RT-qPCR assay for the quantification of leukemia-associated BCR-ABL1 translocation.

Authors:  D Kottwitz; H El Hadi; M El Amrani; S Cabezas; H Dehbi; S Nadifi; A Quessar; D Colomer; Abdeladim Moumen; E L Hassan Sefrioui
Journal:  Int J Hematol       Date:  2015-08-05       Impact factor: 2.490

Review 5.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Authors:  Qingqing Cai; L Jeffrey Medeiros; Xiaolu Xu; Ken H Young
Journal:  Oncotarget       Date:  2015-11-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.